Angelo Sambunaris
Institute for Advanced Medical Research · Atlanta Institute of Medicine and Research
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Angelo Sambunaris as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT02669030 · A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual InsomniaInstitute for Advanced Medical Research, Alpharetta, GA · terminated · Depression, Major Depressive Disorder, MDD · principal investigator
- Ph2NCT01246908 · Efficacy, Safety and Tolerability of CX157 in Treatment Resistant DepressionCeNeRx BioPharma Inc. · completed · Treatment Resistant Depression · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:48 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.Curr Med Res Opin · 2007121 citationsRCR 4.3
- A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.J Clin Psychopharmacol · 201471 citationsRCR 3.3
- Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.Neuropsychopharmacology · 201449 citationsRCR 2.0
- A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.J Clin Psychiatry · 201340 citationsRCR 1.7
- Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.Int Clin Psychopharmacol · 201419 citationsRCR 0.9
- Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.Int Clin Psychopharmacol · 201519 citationsRCR 0.9
- Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.Int Clin Psychopharmacol · 201418 citationsRCR 0.8
- 16 citationsRCR 0.8
- Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.Int Clin Psychopharmacol · 201614 citationsRCR 0.6
- Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.CNS Neurosci Ther · 20098 citationsRCR 0.3